BioNTech Secures Capital Mandate and Board Expansion as Shareholders Back Oncology Pivot

Shareholders approve €129M capital raise and board expansion as BioNTech pivots to oncology; cash burn from R&D leads to site closures but pipeline advances with key data expected in 2026.

BioNTech’s virtual annual general meeting on Tuesday marked a decisive turn in the company’s transformation from COVID-19 vaccine powerhouse to cancer drug developer. Shareholders approved a sweeping set of structural changes, including the authorization of up to €129 million in new share capital — a tool management now has until 2030 to deploy. The vote also cleared the expansion of the supervisory board by two seats, positions earmarked for oncology and clinical development specialists.

The capital mandate represents up to 50% of BioNTech’s current equity base, but the company stressed it is a precautionary measure rather than an immediate fundraising need. The balance sheet remains formidable: nearly €17 billion in cash and equivalents provides a deep cushion as the group funds an expensive pipeline rebuild. That rebuild comes with a price tag that already shows in the numbers. First-quarter revenue slumped to €118.1 million, while the net loss ballooned to US$622.3 million, driven by heavy investment in oncology research.

To slow the cash burn, BioNTech is closing manufacturing sites in Germany and Singapore, aiming for annual savings of roughly €500 million. Those savings will be redirected into the drug-development pipeline, which management has positioned at the heart of a plan to achieve multiple regulatory filings by 2026. The restructuring also includes a profit-transfer agreement with a newly formed subsidiary, BioNTech Discovery GmbH, designed to centralize mRNA research under the founders' leadership.

The market’s reaction has been muted. BioNTech’s stock trades at around €78, a decline of roughly 5% since the start of the year and well below its 52-week high of near €102. The shares have slipped beneath their 50-day moving average, a technical signal that underscores the disconnect between the company’s clinical ambitions and investor sentiment. Yet all analysts covering the stock rate it a buy. Berenberg’s Harry Gillis recently trimmed his price target from US$155 to US$140 following the quarterly report, but maintains that the equity is deeply undervalued, pointing to the cash pile and the oncology pipeline as assets the market is ignoring.

That pipeline is now entering a critical phase. The antibody candidate Gotistobart, which targets certain lung cancer patients, showed a reduction in the risk of death of more than 50% versus standard chemotherapy in the PRESERVE-003 trial. A confirmatory interim analysis from the pivotal Phase 3 study is expected before the end of this year. Meanwhile, the antibody-drug conjugate Trastuzumab Pamirtecan — developed with partner DualityBio — is slated for an FDA filing this year, backed by Phase 2 data in heavily pre-treated endometrial cancer that delivered an objective response rate of nearly 48%. A global Phase 3 study is already under way.

BioNTech has flagged six late-stage data readouts across lung, breast and gastrointestinal cancers for 2026, alongside initial filing plans for the candidate Pumitamig. The company calls next year a make-or-break period. If the clinical results confirm the promise shown so far, the current valuation — depressed by the expensive restructuring and fading COVID revenue — could leave substantial room for upside. For now, the shares remain hostage to the data calendar, with the next catalyst likely to be the Gotistobart Phase 3 readout later this year.